# Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC

> **NCT02194556** · PHASE4 · UNKNOWN · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- EGFR Positive Non-small Cell Lung Cancer
- Adenocarcinoma

## Interventions

- **DRUG:** Sequential and maintenance icotinib
- **DRUG:** Maintenance icotinib

## Key facts

- **NCT ID:** NCT02194556
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-07
- **Primary completion:** 2017-07
- **Final completion:** 2017-07
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2014-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02194556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02194556, "Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02194556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*